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1. Introduction
Thyroid hormones (THs), the only known iodine-containing compounds with biological
activity, are important for normal development of human organism, affecting the function of
virtually all systems [1]. The thyroid gland releases primarily thyroxine (T4), which is con‐
verted in peripheral tissues by the enzyme thyroxine 5’-deiodinase to the active TH form, 3,3',
5-triiodo-L-thyronine (T3) [1]. Thyroid hormone action is predominantly the result of T3
binding to high-affinity nuclear TH receptors (TRs) that have different tissue distribution and
metabolic targets. TRs subsequently interact with specific DNA sequences, called thyroid
hormone response elements (TREs), located in the regulatory region of different target genes
[2]. Although both T3 and T4 enter the cells, only T3 is the ligand for TRs. When T3 binds to
TR, specific co-factors are recruited and transmit signals to basal transcriptional machinery,
thus inducing conformational changes of the chromatin, and making the selected genes
accessible to the transcription process [3]. Accordingly, the transcription of the target genes is
regulated by T3 and, in this way triiodothyronine exerts its biological effects through the
chosen products of the transcription process. There are two thyroid hormone receptor genes,
TRα and TRβ, located in humans on chromosomes 17 and 3, respectively. Although various
TR isoforms have been reported, these isoforms can be categorized into TRα1, TRα2, TRβ1,
which are widely distributed in the body, and a form with more limited expression, TRβ2 [4].
TRα1 and TRβ1 are the major products of TRα and TRβ genes, respectively. Alternative
splicing of the 3'-most exon of TRα1 results in the generation of TRα2. Since the discovery of
these TR isoforms, many studies have attempted to demonstrate their relative contribution to
mediate thyroid hormone action in various tissues. However, a number of tissues that are well
known targets of THs, is so far limited, and include the pituitary, bones, liver, skeletal and
cardiac muscle, fat tissue and developing brain [1]. In addition to the variable expression of
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TRs in different tissues, the role of TH can vary in particular tissues. Likewise, the numerous
effects by a single hormone on so many distinct tissues is surprising and underscores the vital
role of thyroid hormones in cellular function. Therefore, the interpretation of studies on action
of biological TH/TRs axis is dependent on understanding the complex nature of thyroid
hormone action. It was found that TRs are a multi-functional proteins: they act as transcrip‐
tional repressors in the absence of ligand and as transcriptional activators in the presence of
T3 [5]. Of note, there are reports that TRα2 reveals an inhibitory action against other active TRs
[6]. Importantly, the majority of thyroid hormone actions are thought to be mediated by nuclear
receptors, although a wide range of nongenomic effects of TH at the cellular level have been
recognized in the last decade [7]. Cellular uptake of iodothyronines and the nuclear TRs are
not implicated in the nongenomic actions of thyroid hormones. These specific TH activities
have been described to be present in the cell membrane, various organelles, the cytoskeleton,
and in cytoplasm. Plasma membrane-initiated actions of TH begin at αvβ3 receptor for
integrin,which activates ERK1/2-dependant cascade of kinases and culminate in local mem‐
brane processes, like a modulation of ion transport systems or in complex intracellular events,
such as cell proliferation [8].
The objective of this chapter is to provide a current overview of the impact of hyperthyroidism
on physiological hematopoiesis in humans and experimental animals. The molecular mecha‐
nisms involved in thyroid-dependent regulation of hematopoietic cell growth and develop‐
ment, with insight on the effects of hyperthyroidism on hematopoietic stem cell proliferation,
apoptosis and cell cycle have been described. Moreover, the potential direct role of thyroid
hormones in regulating the development of main hematopoietic lineages, erythropoiesis and
leukopoiesis, are discussed. Finally, a summary on hyperthyroidism and its correlation with
thrombocytopoiesis and platelet counts in circulating blood is also given.
2. Hyperthyroidism and hematopoiesis
Thyroid hormones significantly affect the cell cycle, proliferation, apoptosis as well as
differentiation and metabolism in different types of human cells throughout the entire life [9].
THs also play an important role in specific tissues during their growth and development. THs
have been known to be important regulators of bone development and metabolism [10-12]. In
this notion, thyroid hormones may also regulate a wide array of hematological parameters of
peripheral blood due to their potential influence on cell functions of hematopoietic system.
The association of thyroid disorders and abnormalities in hematological parameters is well
known, however, evidence for a role of THs/TRs in hematopoiesis is unclear so far and mostly
indirect. In 1881, Charcot showed for the first time that Graves’ disease is associated with
anemia. Two years later, Kocher observed a decreased number of red blood cells (RBCs) in the
peripheral blood (PB) of patients after thyroidectomy. Likewise, direct and indirect effects of
excessive or insufficient thyroid hormones on hematopoietic cell maturation and function, on
the synthesis and action of hematogenous humoral factors, and on changes in established
blood composition may play a role in the pathogenesis of abnormal functions of hematopoietic
system that accompany different thyroid diseases. Moreover, various abnormalities in
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hematological status that occur in patients with thyroid diseases may range from subclinical
laboratory abnormalities to clinically significant disorders that might strongly complicate the
clinical course of particular thyroid disease. Indeed, erythrocytosis is fairly common in the
course of hyperthyroidism [13-14], and importantly, all parameters involved in erythropoiesis
return to normal, when an euthyroid state is obtained [15]. However, also anemia is present
in 10 to 25 percent of these patients. With regard to white blood cells, elevated, normal, but
also depressed, total leukocyte counts have been reported in hyperthyroid patients. Observing
the specific types of leukocytes in circulating blood, only the slight decrease in the number of
neutrophils and relative increase in the number of eosinophils and mononuclear cells have
been recorded in hyperthyroid patients. Nevertheless, the hyperplasia of all myeloid lineages
in the bone marrow has been described in several cases of hyperthyroidism [16]. Interestingly,
treatment with thyroid hormones has been suggested to improve reconstitution of the immune
system after hematopoietic stem cell transplantation [17]. Besides, the clinical relationship
between thyroid diseases and the hemostatic system was first defined in 1913 by Kaliebe and
coworkers [18]. At that time authors have reported an episode of central vein thrombosis in a
thyrotoxic patient. Different overt thyroid dysfunctions may cause thrombosis or hemorrhage
by affecting primary and secondary physiologic hemostasis as this system requires careful
regulation, also hormonal, in order to work properly [19].
Altogether, according to recent knowledge, the relationship between thyroid diseases and
hematopoiesis is more complex than assumed and there are several molecular and patient-
based studies on this subject in the scientific literature. Nevertheless, appropriate and adequate
studies of high quality are lacking. In most of the reported studies, there are important
methodological limitations, such as lack of control groups, small number of cases, and
heterogeneity in etiology of the diseases, the severity of thyroid dysfunction and the usage of
different laboratory methods. We review here some of the major advances in this area by
initially focusing on what is known about molecular mechanisms of TH action on hemato‐
poietic cells, with the particular insight into hematopoietic stem and progenitor cells, and
discuss the implications of TH functioning in specific hematopoietic lineages. Although there
is a great body of evidence that TH affect early hematopoietic cells in the indirect manner, the
recent studies of our group suggested that THs may play a direct role in the regulation of the
growth and apoptosis of human early hematopoietic cells [20-21].
2.1. Thyroid hormone receptor expression in hematopoietic stem/progenitor cells
In order to prove that thyroid hormones can directly influence hematopoiesis it is necessary
to investigate in the first line the presence of the thyroid hormone receptor in hematopoietic
stem/progenitor cells (HSPC). The expression of different TRs has been documented in mature
cells of mouse bone marrow (BM), particularly in stromal cells [22], as well as in rat BM cells
[23]. Besides, expression of mRNA for TRα1 receptor was reported in mononuclear cells
isolated from human peripheral blood [17]. Recently, our group demonstrated for the first time
that TH receptors (TRα1 and TRβ1) are expressed at mRNA and protein level in human
CD34+HSPCs that were derived from different sources such as bone marrow and peripheral
blood [20]. Importantly, we also analyzed TRα1 and TRβ1 expression in HSPC circulating in
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human umbilical cord blood and we found that TRα1 was expressed in both mRNA and
protein form, however, TRβ1 gene had only the expression at the mRNA and not at the protein
level [20]. The presence of different TRs in human early CD34+hematopoietic cells is summar‐
ized in Figure 1.
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Figure 1. Analysis of TRα1 and TRβ1 expression at transcriptomic and translational level in human CD34+-enriched
hematopoietic stem/progenitor cells. Left panel: expression of mRNA for β-actin (A), TRα1 (B) and TRβ1 (C) in
CD34+human cells obtained from cord blood (CB), peripheral blood (PB), and bone marrow (BM). Right panel: expres‐
sion of protein for TRα1 (D) and TRβ1 (E) in CD34+human cells obtained from bone marrow (BM), cord blood (CB), and
peripheral blood (PB). M-molecular marker of DNA weight. Modified from: [20].
Interestingly, we recently observed that the abnormal concentrations of thyroid hormones may
influence the rate of expression of different TRs in hematopoietic cells. To investigate the
molecular changes underlying the enhanced influence of THs on circulatory HSPCs, we
analyzed the expression of TRα-1 gene in CD34+-enriched HSPCs isolated from the PB of
healthy subjects. When HSPC population was subjected for period of 72 hours to triiodothyr‐
onine at concentration ten times higher than normal physiological concentration (equal to 3.7
pg/mL), which quite resemble the natural conditions of hyperthyroid state in human patients,
the expression of mRNA for TRα-1 gene was down-regulated in the majority of analyzed blood
samples as shown in Figure 2 [21].
Furthermore, our group found that in patients with hyperthyroidism the levels of mRNA for
TRα-1 expressed by CD34+-enriched HSPCs were significantly decreased by around 37%
compared to HSPCs isolated from control healthy subjects (254.9 vs. 398.3, respectively;
amount of the transcript given in arbitrary units; P<0.01) as determined by real-time PCR [21].
Additionally, the results indicating the direct influence of THs on TR expression were
qualitatively corroborated by the immunocytofluorescence analysis of TRα-1 protein expres‐
sion in PB-derived CD34+-enriched HSPCs obtained from patients with overt thyroid dys‐
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function. Here, the fluorescence signal of cells from hyperthyroid patients was much weaker
than signal of equal cell population from healthy donors. Interestingly, HSPCs from hypo‐
thyroid patients presented the most intense fluorescence signal in this analysis performed in
the established and fixed conditions. The summary of data obtained from in vitro investigation
using immunofluorescence to detect TRα-1 protein expression is presented in Figure 3.
Altogether, the above findings may indicate that T3 at high concentration might reduce the
expression of TRα-1 in circulating CD34+-enriched HSPCs due to active trafficking of protein
receptors and possible intense biodegradation after terminating its role in cell signaling. The
process of shuttling of TR between cytoplasm and nucleus directly after TH stimulation was
also observed [24]. Alternatively, a biologically controlled ligand-negative loop that form
homeostatic mechanism regulating cell activity may prevent the possibility that more ligand
binding to specific receptors could actively induce different cellular processes in TR-expressing
cells. Therefore, the active reduction of mRNA expression or inhibition of TR protein produc‐
tion would result in prevention against cellular hyperactivity in the hyperthyroid state of the
organism, also in the hematopoietic cells of patients with hyperthyroidism. Similar data were
obtained by Meier–Heusler et al., who documented a decreased expression of TRβ-1 in
mononuclear cells of peripheral blood from hyperthyroid patients and they noted that the
levels of mRNA for TRβ-1 were about 40% lower than in euthyroid subjects [25]. Correspond‐
ingly, previous observations by Rao et al. suggested a significant trend towards a down-
regulation of TRα-1 mRNA levels in the other tissues under the hyperthyroid state, such as rat
testes [26]. These data suggest that specific cellular TR expression is sensitive to the patholog‐
ical conditions related to hyperthyroidism developed in the affected organism.
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Figure 2. Expression of mRNA for TRα-1 in human CD34+-enriched hematopoietic stem/progenitor cells incubated
with increased concentration of T3. Gene expression of TRα-1 was assessed by real-time RT-PCR in CD34+cells collected
from healthy donors and incubated through 72 hours with serum saline (Control) or with ten times higher than nor‐
mal concentration of T3 (T3 10xN). The amount of the transcript is expressed in the arbitrary units. Each line repre‐
sents TRα-1 expression in cells collected from particular subject [21].
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2.2. Hyperthyroidism and lineage-specific clonogenic growth of hematopoietic cells
The hematopoietic system is very sensitive to thyroid hormones and hyperthyroidism may
induce significant alterations in growth of hematopoietic stem/progenitor cells, originally
located in bone marrow as well as constantly circulating in peripheral blood, and thus
significantly exposed to biologic activity of free THs. Unfortunately, our current knowledge
concerning the influence of THs on clonogenicity of human HSPCs is very limited and mostly
based on studies performed in animal models or human tissues cultured ex vivo. However,
such studies, performed in part also by our group, expanded the understanding of the role of
thyroid disorders in normal human hematopoiesis and could show a direct pathophysiological
influence of T3 on this process.
2.2.1. Erythropoiesis
Erythropoiesis is the physiologic process in which red blood cells (RBCs) are produced.
Hematopoietic development within the erythroid lineage requires a delicate balance between
the opposing effects of proliferation-promoting factors that maintain the renewal capacity of
immature erythroid progenitors and differentiation-inducing factors required for successful
terminal maturation of erythroid progenitors into mature erythrocytes [27]. In vivo, both the
renewal and maturation of human erythroid progenitors proceed in the bone marrow in
Figure 3. Immunocytofluorescence of TRα-1 protein in human CD34+-enriched hematopoietic stem/progenitor
cells. CD34+cells from healthy donors (B), hyperthyroid patients (C), and hypothyroid patients (D) were stained with
anti-TRα-1 antibody (pseudo-colored red). Cell nuclei (A-D) are visualized with DAPI (pseudo-colored blue) [21].
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parallel. Although thyroid hormones are required for normal development and differentiation
of many cell types, little is known about their role in physiologic erythropoiesis, especially in
humans [4]. On one side, hyperthyroidism induced in experimental laboratory animals or in
humans, generates increased RBC number and total RBC mass through stimulation of
erythropoiesis [28-29], however, it has been postulated that this effect would be indirect and
involves modulating function of biologically active substances important for erythropoiesis,
such as kidney-derived erythropoietin (EPO) or other hematogenous humoral factors, which
production by non-erythroid cells is also increased in hyperthyroid state [30-31]. Besides, there
are evidences that THs may increase the concentration of 2,3-diphosphoglycerate in erythro‐
cytes, which serves to enhance the delivery of oxygen to tissues, and thus affects steady-state
levels of circulating EPO [32-33]. Interestingly, in vitro studies confirmed that both T4 and T3
stimulate EPO synthesis in the human liver cell line HepG2 and this stimulating effect could
persist for 24 hours after the removal of THs from the cell culture [34]. However, in the
established model of HSPCs cultures in vitro with standard amount of EPO performed for
analysis of differential clonogenic growth of hematopoietic cells, we observed that prolifera‐
tive potential of burst-forming units of erythrocytes (BFU-E) was increased only in the samples
collected from the patients with hyperthyroidism and, in contrast, it was decreased in case of
samples collected from the hypothyroid subjects [21]. Therefore, it seems that THs can induce
signal transduction pathways implicated in proliferation of hematopoietic progenitors for
erythroid lineage other than EPO-dependent mechanisms. Data from in the available literature
corroborate our discovery indicating the direct role of THs in normal erythroid differentiation
of human and animal origin [35-38]. For example, daily administration of thyroxine into mice
stimulated the increase of indices significant for RBC production, such as packed red blood
cell volume, total circulating RBC count and mass, and reticulocyte count [39]. Likewise,
Malgor et al. have studied the TH role on modulation of erythropoiesis using the in vitro
cultures of cells collected from bone marrow of normal rats in the absence of EPO [37]. They
found that T3 produced a direct and significant stimulation of clonogenic growth of late
colony-forming erythroid units (CFU-E) and a moderate increase of early erythroid burst-
forming units (BFU-E) indicating an enhanced proliferative activity of committed erythroid
progenitors in response to this hormone. In contrast, the addition of T3 to in vitro cultures of
avian BM cells activates the TRα receptor in avian erythroblasts, blocks their self-renewal, and
induces synchronous, terminal differentiation of erythroid lineage from hematopoietic
progenitor cells [40]. Notwithstanding, Kendrick et al. recently verified the essential function
of TRα in regulating erythropoiesis in mammals by characterizing the phenotype of TRα−/−
mice deficient for TRα. These transgenic mice had significantly reduced numbers of erythroid
progenitor cells in the fetal liver, decreased hematocrit in adult organism, and a diminished
erythroid stress response to hemolytic anemia [41]. Similar results of direct TH influence on
erythroid lineage growth were taken from observations of human erythropoiesis developed
in vitro in established conditions. In pioneer studies of human BM-derived cells and THs action
Golde et al. showed that THs do not shift the requirement for EPO in the course of human
erythropoiesis, but both substances have synergistic effects in increasing the number of
erythroid colonies growing in vitro [35]. These data were corroborated by Leberbauer et al.,
who recently demonstrated that terminal erythroid maturation in course of development of
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human erythroblasts obtained from umbilical cord blood is significantly improved by
supplementation of T3 to the defined culture medium [42]. Likewise, we performed a quan‐
titative molecular analysis of hematopoietic stem/progenitor cell proliferation based on the
expression levels of mRNA for the Cyclin D1 and PCNA genes, which are concerned to be
important for the cell cycle regulation. We found in our study, the nearly 100% increase in
expression of mRNA for both analyzed genes in PB-derived CD34+-enriched HSPCs collected
from subjects with hyperthyroidism (Figure 4), thus indicating that THs significantly stimu‐
lates up-regulation of genes involved in the induction of hematopoietic cell proliferation [21].
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Figure 4. Expression of mRNA for PCNA and Cyclin D1 in human CD34+-enriched hematopoietic stem/progenitor cells
collected from hyperthyroid patients. Gene expression of PCNA (panel A) and Cyclin D1 (panel B) was assessed by real-
time RT-PCR in CD34+cells isolated from PB of patients with hyperthyroidism and healthy donors (Control). The mean
amount of the selected gene transcript (± SD) is expressed in the arbitrary units. P < 0.05. [21]
These molecular data correlate strongly with increased potential of erythroid progenitor cell
growth observed in our study performed on CD34+-enriched HSPCs from PB of patients with
thyroid dysfunction using in vitro proliferation assays [21]. Erythroid BFU-E colonies culti‐
vated from CD34+cells that were collected from circulating blood of patients with hyperthyr‐
oidism exhibited in average a 40% increase of their clonogenic growth compared to the healthy
control group (P<0.05). Importantly, in the group of patients with hyperthyroidism comprised
of 25 persons of whom 52% were patients with Graves’ disease and 48% with toxic nodular
goiter, we also observed a significant increase in the number of mature RBCs in the PB.
Furthermore, RBCs from our cohort possessed increased mean corpuscular volume, but
reduced mean corpuscular hemoglobin concentration and mean hemoglobin mass. These
findings together might indicate that erythroid progenitors that are overproduced in BM of
hyperthyroid patients under the abnormal T3 stimulation would generate mature RBCs
circulating in excess in peripheral blood. However, cellular structure and composition of
circulating RBCs was also affected. Of note, our study group presented the mild increase in
free T3 concentration compared to healthy volunteers who served as control group (2.71±1.14
vs. 6.95±3.13 pg/mL of T3, respectively).
However, there is a few studies with contradictory results investigating the functional effect
of thyroid abnormalities on the RBC counts in peripheral blood. Gianoukakis et al. have
measured the RBCs in 87 hyperthyroid patients with Graves’ disease and 19 healthy subjects.
The average number of RBCs was found to be lower in the 36% of recruited hyperthyroid
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subjects compared to the healthy individuals. Nevertheless, in the group of selected patients
with anemia, the mean EPO levels were significantly higher (P=0.004) than those of the non-
anemic controls [43]. According to other authors, anemia is present in 10 to 25 percent of
patients with hyperthyroidism [15, 44]. This finding may be the result of increased plasma
volume, as reported effect of increased T3 concentration in humans [45] and animal model [39],
but also the result of autoimmune processes leading to anemia in Graves’ disease, such as
pernicious anemia and autoimmune hemolytic anemia, which concurrently may develop [46].
In addition, decreased RBC survival and ineffective erythropoiesis in course of hyperthyroid‐
ism have been described [47-48]. Pancytopenia in the setting of hyperthyroidism has also been
reported in the literature. Most cases of pancytopenia have been associated with Graves’
disease and one case with toxic adenoma, and TH-related stem cell dysfunction has been
suggested there as one possible mechanism among others [49-51]. Likewise, our group
observed that heavily non-physiological concentrations of T3, such as ten times higher or fifty
times higher than physiological concentration of free T3 significantly negatively influenced
the in vitro growth of erythroid BFU-E colonies in proliferation assays derived from human
CD34+HSPCs circulating in peripheral blood. This effect was even more noticeable after
prolonged exposure to increased non-physiological T3 amounts [20]. This may explain the
abnormalities in RBC counts observed in some patients with hyperthyroidism, especially those
with advanced and chronic disease. In contrast, the in vitro clonogenic potential of erythroid
BFU-E progenitors was considerably increased in physiological concentration of free T3 as well
as in mildly increased concentration of T3 such as five times higher than normal physiological
one [21]. The mean numbers of the colonies of erythroid BFU-E obtained in our study are
presented in Table 1.
Free T3 concentration N 5xN 10xN 50xN
Parameter Incubation % % % %
Growth of BFU-E from BM 24 hours 100.00 103.5 ± 30.7 85.6 ± 29.1 70.6 ± 54.4
72 hours 100.00 108.9 ± 43.9 88.25 ± 46,9 49.2 ± 18.2*
Growth of BFU-E from PB 24 hours 100.00 114.0 ± 42.9* 104.0 ± 20.2 65.0 ± 12.2*
72 hours 100.00 101.0 ± 50.3 63.0 ± 36.2 59.0 ± 13.9*
Growth of BFU-E from CB 24 hours 100.00 94.9 ± 32.2 88.8 ± 39.2 58.0 ± 31.9
72 hours 100.00 90.5 ± 18.9 66.5 ± 11.6* 46.9 ± 14.5*
Table 1. Influence of T3 on clonogenicity of human BFU-E after 24-and 72-hour incubation with increasing free T3
concentrations. Cells (n=5) incubated with: N=physiological dose of T3 (3.7 pg/mL); 5×N=five times higher than N;
10×N=10 times higher than N; 50×N=50 times higher than N. Results are expressed as mean percentage (± SD) of the
control value obtained with established physiological dose of T3 taken as 100%. P < 0.05 [20].
2.2.2. Leukopoiesis
Leukopoiesis is the process of white blood cells (WBCs) formation from hematopoietic stem
cells placed in hematopoietic organs. Leukocytes are a heterogeneous group of blood cells that
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all have nuclei and include granulocytes (i.e. neutrophils, eosinophils, and basophils),
monocytes, lymphocytes T and B, as well as natural killer cells. Leukopoiesis is stimulated by
different cytokines, interleukins, colony-stimulating factors and several hormones. The body
of information on the relationship between thyroid hormones and WBC biology is relatively
large and describes contribution of thyroid hormones to the modulation of physiological
leukocyte activities such as chemotaxis, phagocytosis, respiratory burst, cytolytic activity, and
cytokine synthesis in monocytes/macrophages and different types of lymphocytes. Neverthe‐
less, the data available are frequently difficult to interpret or even contradictory, when related
to growth and proliferation of specific leukocyte types. This situation is even more complicated
by the fact, that WBCs are able to produce several hormones or hormone-like molecules [52],
and the expression of thyroid hormones has been reported in several WBCs, like monocytes,
granulocytes, natural killer cells, mast cells, and lymphocytes [53-54]. It is also known that T3
is able to modulate functions of immune-related cells either via nuclear receptors that are
responsible for genomic TH activities, and by interactions with other membrane receptors for
THs that conduct non-genomic actions of THs [1].
In general, it was found that physiological concentrations of thyroid hormones positively
correlates with the immune cell parameters/functions, such as cell counts and induction of
different physiological activities of particular WBC populations. Few reports analyzing the in
vitro actions of THs showed modifications in lymphocyte reactivity [55-56]. However, the
direction and magnitude of these alterations might depend on the type and concentration of
the TH encountered by the responding cells, and the species source of lymphoid cells. For
example, it was found that THs within the normal physiological range may increase a mitogen-
induced normal T lymphocytes proliferation through both the genomic and non-genomic
mechanisms [57]. Furthermore, Hodkinson et al. measured plasma thyroid hormone levels in
93 late-middle aged healthy euthyroid subjects, and calculated the mean T3/T4 ratio, and next
used these numbers to distinguish between low-and high-thyroid hormones concentration,
but still within the normal physiological range, and found a significant positive association
between thyroid hormones concentration and natural killer T-cell percentage and monocytes
count [58]. In addition, in the same study there was also a significant inverse association of
THs levels with the expression of early lymphocyte apoptosis markers [58]. Recently, it has
been proposed that thyroid hormones are significant for leukopoesis as highly involved in
maintaining immune system homeostasis in response to environmental changes or stress-
mediated immunosuppression [59]. Further evidences from studies on mammals indicate that
thyroid hormones have important immunomodulatory effects. Likewise, T3 enhances
phytohaemagglutinin stimulation of human lymphocytes [60]. Concurrently, El-Shaikh et al.
have shown that the daily subcutaneous supplementation of T4 in BALB/c mice for one month
induces an increase in the total number of peripheral blood leukocytes, as well as augments
cellularity of thymus and spleen parenchyma, and peripheral lymph nodes [61]. In general,
developed hyperthyroid state induces the increase in the immune system functions related to
the antibody production, immune cell migration, and reactive oxygen species production,
whereas it decreases the proinflammatory markers expression, the antioxidant enzymes
production, and their cellular activity [62]. Notwithstanding, in other in vivo study performed
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in rats, the induction of hyperthyroidism did not affect the ratio of helper to suppressor T
lymphocytes in the examined immune system [63].
Due to the contrasting results revealed in some previous reports, it is quite difficult to establish
a clear correlation between hyperthyroidism and immune functions [62]. These discrepancies
may be largely attributed to differences in the duration of disease, age and gender of animal
and human subjects and hyperthyroidism origin, or even the treatment mode given to the
patients with thyroid disease. Especially, previous studies on human different WBC popula‐
tion counts and function during hypo-and hyperthyroid states produced conflicting results.
Indeed, a significant decrease in the lymphocyte and increase in monocyte count were
observed in patients with autoimmune thyroiditis [64], however, similar changes in the
number of lymphocytes were also observed in autoimmune hyperthyroidism [65]. Thus, it is
supposed that the changes in number of lymphocytes in different thyroid autoimmune
dysfunctions are due to the autoimmune process alone, and not due to the direct influence of
thyroid hormones specifically on lymphopoiesis. Possibly, the elevated number of lympho‐
cytes in autoimmune-related thyroid disorders may demonstrate a nonspecific activation of
the immune system as it is found in some other autoimmune-derived diseases in humans
[66-67]. Our own results performed in the selected group of patients with hyperthyroidism
showed a tendency to decrease the general WBC number in circulating peripheral blood. Thus,
we were mostly interested in biology of hematopoietic stem and progenitor cells of myelo‐
monocytic lineage from these subjects, as appeared that this lineage may be clearly independ‐
ent from autoimmune responses developed in this patient group and might be affected by
abnormal THs concentration. It appears from the available literature that the relationship
between thyroid hormones and myelopoiesis has been studied mainly based on hematopoietic
cells collected from peripheral blood of healthy subjects. Unfortunately, the current knowledge
concerning the influence of THs on clonogenicity of progenitors for granulocytes and mono‐
cytes that grown as colony forming units of granulocytes and monocytes (CFU-GM) is very
limited. There are only few reports on the influence of physiological T3 concentration on
clonogenic potential of human CFU-GM cells. For example, Notario et al. observed that both
thyroid hormones, T3 and T4, are able to enhance the colony growth of CFU-GM obtained
from normal PB, and interestingly, the response is more evident for T4 than T3 [68]. Moreover,
the second report of this group revealed that there is a synergistic effect of THs and different
hematopoietic growth factors, like G-CSF, GM-CSF, and IL-3, which are substantial for
proliferation of progenitors for myelomonocytic lineage [69]. In contrast, Ponassi et al. reported
an abnormal granulopoiesis in nearly 50 percent of patients with untreated Graves' disease,
based on the pharmacological test with mobilization of the marrow granulocyte reserve by
hydrocortisone [70]. However, no data on clonogenic potential of hematopoietic progenitor
cells in the presence of different nonphysiological concentrations of thyroid hormones were
reported in either of these studies. Therefore, our group recently analyzed the in vitro growth
of myeloid CFU-GM colonies derived from human CD34+HSPCs in proliferation assays with
growing non-physiological concentrations of free T3. We observed that clonogenic potential
of CFU-GM colonies from CD34+HSPCs of healthy subjects was considerably increased in
concentration of T3 only moderately higher (5x) than the physiological T3 concentration [20].
In contrast, the much higher non-physiological concentrations of T3, such as ten times higher
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or fifty times higher than physiological T3 concentration significantly negatively influenced
the growth of myeloid CFU-GM colonies derived from CD34+HSPCs collected from peripheral
blood as well as umbilical cord blood. This effect was even more significant in case of myeloid
CFU-GM colonies derived from CD34+HSPCs harvested from the bone marrow of healthy
donors [20]. In addition, we noticed an enhanced negative effects of non-physiological
concentrations of T3 in the case of prolonged in vitro exposure to the triiodothyronine (72-
hour-period). The mean numbers of the colonies of myeloid CFU-GM obtained in our study
are presented in Table 2.
Free T3 concentration N 5xN 10xN 50xN
Parameter Incubation % % % %
Growth of CFU-GM from BM 24 hours 100.00 77.8 ± 19.6* 72.6 ± 18.7* 50.1 ± 8.7
72 hours 100.00 91.0 ± 36.7 97.2 ± 47,7 49.2 ± 18.2*
Growth of CFU-GM from PB 24 hours 100.00 154.0 ± 18.7* 101.0 ± 14.5 90.0 ± 35.8*
72 hours 100.00 292.0 ± 26.6* 205.0 ± 17.5* 141.0 ± 29.4*
Growth of CFU-GM from CB 24 hours 100.00 106.3 ± 28.4 92.7 ± 11.6 93.8 ± 35.7
72 hours 100.00 96.1 ± 16.2 65.1 ± 9.9 55.9 ± 7.5
Table 2. Influence of T3 on clonogenicity of human CFU-GM after 24-and 72-hour incubation with increasing free T3
concentrations. Cells (n=5) incubated with: N=physiological dose of T3 (3.7 pg/mL); 5×N=five times higher than N;
10×N=10 times higher than N; 50×N=50 times higher than N. Results are expressed as mean percentage (± SD) of the
control value obtained with established physiological dose of T3 taken as 100%. P < 0.05 [20].
The abovementioned results clearly correlated with clonogenic potential of CD34+-enriched
HSPCs collected from subjects with diagnosed thyroid dysfunction [21]. In our clinical study,
we examined the clonogenicity of CD34+HSPCs harvested from PB of hyperthyroid patients
using the in vitro proliferation assays, and we found that the number of CD34+-expanded CFU-
GM colonies was significantly lower in this group than that observed in healthy euthyroid
subjects (66 vs. 100% respectively; P < 0.05).
One of the possible explanations for the diminished clonogenic growth of CFU-GM derived
from hyperthyroid patients might be the TH-dependent cell death induced in circulating
and BM residual HSPCs. Cell death has been broadly classified into two categories, necrosis
and apoptosis. Of note, there is ongoing debate as to the mutually exclusive nature of these
two  categories  of  cell  death,  and  it  seems  possible  that  there  are  many  intermediate
subcategories.  However,  necrotic  cell  death  is  always  a  pathological  event  occurring  in
response to strong cell/tissue injury or environmental  insult.  In contrast,  apoptosis is  an
energy-requiring process that often involves altered expression of key cell proliferation and
death-inducing  genes.  It  is  known that  THs,  like  many other  hormones  acting  through
nuclear receptors, are important regulators of cellular proliferation and apoptosis [71-72].
At the cellular level, both T3 and T4 induce apoptosis in different cell types, like rat pituitary
cell lines [73-74], rat cardiomyocytes [75], and human breast cancer cells [76], when exposed
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to THs in vitro or in vivo. It was observed that in HeLa cervix cancer cell line T3 indu‐
ces caspase activity, which plays a key role in the execution of apoptosis [77]. In contrast,
the  physiological  concentrations  of  both  T3  and  T4  inhibited  apoptosis  in  rat  brain-
derived  endothelial  cells  in  vitro  through  alterations  in  the  mRNA levels  of  apoptosis-
related genes, such as BCL-2 and BAD [78]. T4 was able to inhibit the resveratrol-induced
apoptosis  in  glioma cells  in  vitro  through nongenomic  mechanisms,  employing integrin
receptor  and ERK-mediated cascade [79].  Alike,  previously  mentioned Hodkinson et  al.
observed that under normal physiological conditions T3 reduced incidence of lymphocyte
apoptosis in healthy older individuals [58]. Similarly, Barreiro Arcos et al. observed, that
TH treatment augments the mitogen-induced proliferation of normal T lymphocytes [80].
Altogether, TH-mediated effects on cellular apoptosis depend on the type and developmen‐
tal or pathophysiological state of the selected cells and tissues. Importantly, there are many
compounds and circumstances that can induce cell apoptosis. It is known that a particu‐
lar agent may produce apoptosis in a given cell or tissue, but may not in another, or in a
given cell at one period of the cell cycle, but not at another. Whether a cell responds to
such an agent by induction of  programmed cell  death,  it  must therefore depend on the
specific array of interactive molecular regulatory systems active in that cell at that time [81].
In  case  of  cells  related  to  hematopoietic  system,  the  pro-apoptotic  actions  of  THs were
defined in normal and tumor-derived lymphocytes. In this notion, Mihara et al. demonstrat‐
ed that T lymphoma cells from the human Jurkat cell line, cultured in vitro for 2 weeks
with addition of T3 and T4, showed their enhanced apoptosis [82]. This group also showed
that T lymphocytes from healthy volunteers cultured with T3,  but not T4,  for five days
exhibited an increase in the percent of spontaneous apoptosis,  thus indicating that long-
term exposure to T3 induces accelerated lymphocyte apoptosis in vitro [82]. Indeed, Mihara
and coworkers found also significantly higher percentage of apoptotic T lymphocytes in
vivo  from patients  with  chronic  Graves’  disease  than from healthy  subjects  [82].  More‐
over, Gandrillon et al. determined that THs increased apoptosis rate in early erythrocytic
progenitor cells [83], and similar effect was observed by Hara et al. in hematopoietic HL-60
cells of promyeloleukemic lineage [84]. To put the light on the possible pathophysiologi‐
cal  mechanisms  of  such  decreased  proliferative  potential  of  CD34+HSPCs  in  high  non-
physiological  T3  concentrations  reported  by  our  group,  we  analyzed  the  process  of
apoptosis in HSPCs collected from different compartments of human hematopoietic system,
such as  bone  marrow,  peripheral  blood or  umbilical  cord blood [20].  In  our  study,  we
performed the analysis of potential influence of T3 on the apoptosis induction in human
CD34+-enriched hematopoietic progenitor cells collected from the above hematopoietic cell
sources of healthy subjects. Importantly, we analyzed the apoptosis in these cells employ‐
ing three different molecular techniques as, according to specialists in this field, it is crucial
for reliable detection of this phenomenon to confirm it by applying at least three distinct
laboratory methods. For this reason, we used the flow cytometry-based detection of annexin-
V, TUNEL technique detecting apoptosis-related abnormalities in cell genetic material, and
finally,  analysis of the expression level of pro-apoptotic Bax  and both anti-apoptotic Bcl-
xL and Bcl-2 genes in the CD34+HSPCs that were incubated with different non-physiologi‐
cal T3 concentrations (5×N; 10×N; and 50×N; where N is equal to established physiological
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T3 dose) for period of 24 or 72 hours. We found that after 24 hours all  three used non-
physiological T3 concentrations markedly induced the apoptosis in analyzes hematopoiet‐
ic progenitors, however the percentage of apoptotic CD34+HSPCs was significantly higher
in samples collected from PB, CB and BM incubated with the highest dose [20].  Similar
results were obtained for longer incubation through 72-hour-period. It was especially clearly
noticeable in the detailed analysis of the apoptosis detected by TUNEL technique present‐
ed in Table 3. Correspondingly, when analyzing the mRNA expression for genes crucial
for  apoptosis  in  human  early  hematopoietic  CD34+cells  after  incubation  with  the  fixed
increasing T3 concentrations, we observed an augmented expression of pro-apoptotic BAX
gene and decreased expression of the anti-apoptotic genes: BCL-xL and BCL-2 in these cells
under  exposure  to  T3  amount  50  times  higher  than  the  established  physiological  T3
concentration [20].
Free T3 concentration N 5xN 10xN 50xN
Parameter Time % % % %
Apoptotic CD34+ HSPCs from BM 24 hours 100.00 144.5 ± 39.4* 94.3 ± 33.9 87.4 ± 47.6
72 hours 100.00 179.0 ± 25.5* 107.3 ± 9,6 119.1 ± 11.0*
Apoptotic CD34+ HSPCs from PB 24 hours 100.00 115.1 ± 20.5 166.6 ± 31.7* 98.8 ± 20.4
72 hours 100.00 105.3 ± 36.5 122.5 ± 17.8* 125.1 ± 16.1*
Apoptotic CD34+ HSPCs from CB 24 hours 100.00 105.3 ± 36.5 122.5 ± 47.8 105.1 ± 26.1
72 hours 100.00 167.8 ± 6.9* 177.4 ± 34.6* 213.6 ± 32.0*
Table 3. Percentage of apoptotic cells detected with the established TUNEL method after 24-and 72-hour incubation
of human CD34+cells with increasing free T3 concentrations. Cells (n=5) incubated with: N=physiological dose of T3
(3.7 pg/mL); 5×N=five times higher than N; 10×N=10 times higher than N; 50×N=50 times higher than N. Results are
expressed as mean percentage (± SD) of the control value obtained with established physiological dose of T3 taken as
100%. P < 0.05 [20].
Our group was also interested to assess the influence of THs on apoptosis rate in PB-derived
CD34+HSPCs circulating in peripheral blood of the patients with hyperthyroidism [21]. For
this analysis, we used combined annexin-V and propidium iodate staining of hematopoietic
cells detected by flow cytometry. This method especially provides the chance to assess
apoptosis in two distinct stages, the early and late phase of apoptosis. In fact, we observed a
significant increase in the percentage of cells undergoing the late, executive phase of apoptosis
in the group of patients with hyperthyroidism compared to euthyroid control subjects (1823.43
± 1334.15 vs. 100% of the control population, respectively; P<0.05). The results are displayed
in Figure 5. However, there were no differences between analyzed groups in percentage of
CD34+cells undergoing the early stage of apoptosis (103.1 ± 74.16 vs. 100% of the control
population, respectively).
Concurrently, expression of mRNA for BCL-2 and BCL-xL genes was assessed by real-time RT-
PCR in CD34+cells isolated from PB of patients with hyperthyroidism and healthy controls.
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We found that both examined anti-apoptotic genes, BCL-2 and BCL-xL, were significantly
down-regulated compared to healthy volunteers (40% and 67% vs. 100% respectively; P<0.05).
In the same manner the expression of BAX gene of pro-apoptotic activity was analyzed.
Interestingly, this gene was also significantly down-regulated compared to control subjects
(36% vs. 100% respectively; P<0.05). The above data strongly correlate with the previously
observed tendency to decrease the clonogenic potential of CD34+hematopoietic stem/progen‐
itor cells of myeloid lineage of hyperthyroid subjects and may indicate that THs at higher
concentrations negatively modulate the expression of genes important for hematopoietic cell
survival, such as anti-apoptotic BCL-2 and BCL-xL genes. On the other side, the parallel
decrease of expression level of pro-apoptotic BAX gene might be related with significant
augmentation of late, executive phase of apoptosis in circulating CD34+cells due to the chronic
exposure to elevated concentrations of T3 found in hyperthyroid patients (Fig. 5). Indeed, BAX
is expressed at high levels during the period when programmed cell death is activated by
intracellular or extracellular stimuli, and down-regulation of the gene expression occurs
thereafter, when signal transduction pathways triggered the performance of apoptotic protein
cascade inside the cell [21].
2.2.3. Thrombocytopoiesis
Thrombocytopoiesis is the process of thrombocyte generation from the cytoplasm of mega‐
karyocytes located in bone marrow hematopoietic niche. Megakaryocyte maturation comes to
completion with the release of thrombocytes, known as platelets, into the bloodstream and
each day an adult produces about 100 billion platelets. They are necessary for normal blood
clotting. Megakaryocytes normally account for 1 out of 10.000 bone marrow cells but their
 
*  
Figure 5. Percentage of human CD34+-enriched hematopoietic stem/progenitor cells in the late apoptotic stage col‐
lected from hyperthyroid patients. Apoptosis in hematopoietic progenitor cells collected from patients with hyper‐
thyroidism and healthy subjects (Controls) was scored by cytometric detection of annexin-V and propidium iodate.
Results are expressed as mean percentage (± SD) in relation to control values considered as 100%. *P<0.05 vs. con‐
trols. [21]
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number can increase or decrease in the course of certain diseases, thus resulting in abnormal
megakaryocyte function and abnormal platelet quantity or function, and this influences
hemostatic system in peripheral blood [85]. In the specialized microenvironment of the bone
marrow the megakaryocyte development and subsequent platelets production is regulated
through a complex crosstalk between many cell types and cytokines. Especially, thrombo‐
poietin was identified as the major regulator of platelet production, however, other biologically
active substances, such as hormones, may play an important role in the regulation of mega‐
karyocyte growth and proliferation [86].
Exactly, one century ago appeared the first report of Kaliebe et al. indicating the clinical
relationship between thyroid disease and the dysfunction in hemostatic system. In 1913 the
authors have described an episode of central vein thrombosis in a thyrotoxic patient and this
medical report was later summarized in 1927 by Doyle, who was studying a possible associ‐
ation between thyrotoxicosis and cerebral vein thrombosis in patients with neurological
symptoms [87]. Likewise, various diseases of hemostatic system, ranging from hemostasis
disorders, and rarely life-threatening hemorrhages to hypercoagulability and thrombotic
events, could be observed in parallel to thyroid gland dysfunctions. However, some contra‐
dictory results regarding hemostatic system functions have been obtained in clinical studies
of patients with thyroid disorders.
Several published reports have shown a hypercoagulable state in patients with hyperthyroid‐
ism [19, 88]. For certain, patients with hyperthyroidism showed a tendency toward thrombo-
embolic process (8–40%), including major emboli at cerebral vasculature, which accounts for
nearly 18% of all deaths associated with thyrotoxicosis [89]. Another systematic analysis also
supports an increased risk of venous thrombotic complications, including cerebral venous
thrombosis, deep vein thrombosis and pulmonary embolism in patients with hyperthyroidism
[90]. Hypercoagulability state that is observed in hyperthyroidism is produced by various
coagulation factor (e.g. clotting factors and their inhibitors) abnormalities that occur in patients
with hyperthyroidism and are not directly related to thrombocytes and thrombocytopoiesis.
Researchers hypothesized that THs may affect the synthesis of many proteins originating from
the liver and endothelium by altering the specific gene expression. Indeed, collected data have
specified that hyperthyroidism, regardless of its etiology, influences endothelial function by
up-regulating the expression levels of vascular adhesion molecules and endothelium-derived
proteins important for fibrinolysis, such as tissue-type plasminogen activator and plasmino‐
gen activator inhibitor-1 [91]. On the other hand, it is known that there is a general increase of
metabolism in hyperthyroid state, which may affect cell components of the peripheral blood
and bone marrow. Likewise, it was found that the life-span of platelets is shortened in patients
with hyperthyroidism resulting in thrombocytopenia [92]. Moreover, the same group ob‐
served that the platelet count increased upon reduction of the concentration of circulating
thyroid hormones [92]. Similar data were obtained by Kurata et al., who showed that the
platelets count are low and their lifespan shorter in almost one-half of 214 studied patients
with Graves’ disease [93]. Notwithstanding, thrombocytopenia in patients with hyperthyr‐
oidism may have several causes, such as autoimmunity against thromobocytes [94-95] in
parallel to nonspecific thyroid antibodies binding to platelets that augment their non-specific
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degradation or due to thrombocyte clearance from plasma by the enhanced phagocytic activity
of the reticuloendothelial system [96]. Finally, detected relative low platelet quantities could
be due to increased circulating blood volume observed in patients with hyperthyroidism, as
in case of other hematologic parameters of blood. Of note, patients with hyperthyroidism had
significantly higher risks of having co-morbidities such as hypertension, hyperlipidemia, and
diabetes that might affect the survival of platelets and their bone marrow progenitors.
Although the pathomechanism is still not well known, altered glucose and lipid metabolism
has been often reported in patients with hyperthyroidism [97]. Altogether, the above-men‐
tioned studies have indicated that hyperthyroidism is associated with either increased blood
coagulability and endothelial cell dysfunction based on examining the incidence of venous
thrombosis, or with thrombocytopenia and decreased life-span of platelets, however, only few
scientists attempted to explore the bone marrow-related mechanisms of abnormal functions
of hemostatic system among patients with hyperthyroidism. Even the recent development of
efficient megakaryocyte cultures in vitro that produce functional platelets has provided the
means to study the biology of megakaryopoesis in abnormal pathophysiological conditions,
such as hyperthyroid state, the number of reports covering this field is very scanty. In one
attempt, to check whether non-physiological THs concentration may directly affect platelet
production, it was necessary to determine the quantity of reticulated platelets (RP) circulating
in peripheral blood. RP represent young cells recently released from the bone marrow, and
according to some reports, their number in peripheral blood reflects thrombopoietic activity
[98]. Indeed, Stiegler et al. confirmed that hyperthyroidism was associated with an increased
marrow thrombocytopoiesis resulting in elevated RP counts. Moreover this finding was
corroborated by observation that RP increase in course of hyperthyroidism was reversible
upon achievement of euthyroid state [99]. Furthermore, to confirm the clinical reports
indicating that excessive THs exert depressive effects on platelets production, Sullivan et al.
used a mouse model to investigate the effects of the hyperthyroid state on thrombocytopoiesis
in vivo by administration of T4 into normal healthy mice. They observed that daily thyroxine
administration significantly decreased total circulating platelet count and platelet mass due to
decreased platelet production. This mechanism was confirmed using the most sensitive
methods of assessing platelet production, i.e. percentage of S-35 incorporation into platelets
and determination of megakaryocyte size and number [39]. Likewise, Sullivan and coworkers
observed that percentage of S-35 incorporation into platelets was reduced and megakaryocyte
size and number in bone marrow were considerably decreased [39]. These are only a few
available evidences that hyperthyroidism plays a direct role in the fine regulation of throm‐
bocytopoiesis in vivo.
3. Conclusion
In recent years there have been published several studies indicating that the thyroid dysfunc‐
tion could have important implications in human hematopoiesis, and thus might affect various
hematological parameters of circulating blood. This chapter demonstrates that hyperthyroid
state might be responsible for profound disturbances in functions of the hematopoietic system
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due to the fact that THs modulate hematopoietic cell production in the bone marrow. The
hyperthyroidism-related symptoms in peripheral blood comprise increased plasma volume,
anemia (10-25%), leukopenia (10%), neutropenia, lymphopenia, thrombocytopenia, decreased
MCV, and reduced RBC survival, as well as general pancytopenia. Of note, erythrocytosis,
lymphocytosis and increased counts of monocytes are also fairly common. Potential molecular
mechanisms of reported hematologic symptoms has been explained in part in this paper.
Importantly, increased thyroid hormone concentrations influence the mechanisms of the
development of hematological abnormalities through both genomic and non-genomic actions.
As a result, in patients with different thyroid endocrinopathies, overt hyperthyroidism should
be also considered as a possible cause of clinically detectable abnormalities in peripheral blood
of these patients. Novel pathophysiological insights into the mechanisms of thyroid hormone
actions in the hematopoietic system may help to improve the understanding of the interactions
between THs and human hematopoiesis and offer a potential for the future development of
novel therapeutic interventions in thyroid diseases.
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